Biogen Inc.

NASDAQ:BIIB

Drug Manufacturers - General

Healthcare
$251.41 -1.11%

-$2.21 today

Market cap
$37.16B
Beta
0.18
P/E (TTM)
21.1
EPS (TTM)
$9.32
52W Low $121.05High $205.97

Volume 1.14M

Average 1.17M

BIIB Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Biogen Inc.NASDAQ: BIIB

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization growth accelerates

Q2 FY2026 depreciation & amortization of $236.1M rose 21.5% year over year, ahead of the +13.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 15.5% from the prior quarter. Over 3 fiscal years it compounded at +14.6% a year.

Context

  • Depreciation & amortization amounted to 7.9% of revenue in FY2025, up 1.0 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +21.5% holds above the trailing-twelve-month pace of +13.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$236.1M+15.5% QoQ
Last fiscal yearDec 2025
$779.9M+15.8% YoY
LTMJun 2026
$842.9M+13.2% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+21.5%——
1 year+15.8%——
3-year CAGR+14.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
779.9M USD
Year-over-year change
+15.8%
4-year CAGR
+12.5%

Depreciation & Amortization vs competitors

How BIIB compares with its peers on the latest reported figures

  • BIIB's LTM Jun 2026 depreciation & amortization of $842.9M is the 5th largest of the 11 companies compared; the peer median is $375.35M.
  • Its year-over-year change of +13.2% is the 5th highest of 11, against a peer median of +11.0%.
  • Depreciation & amortization amounts to 8.5% of revenue for BIIB, versus a peer median of 3.2%.
BIIB Competitors Peer median
Depreciation & Amortization for BIIB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PFEPfizer Inc.LTM Jun 2026$6.58B -3.0%+9.2%10.3%
AZNAstraZeneca PLCLTM Sep 2026$6.41B +29.8%+3.0%10.3%
AMGNAmgen Inc.LTM Jun 2026$4.67B -15.5%+14.8%12.2%
LLYEli Lilly and CompanyLTM Jun 2026$2.1B +10.9%+9.5%2.6%
BIIBBiogen Inc.LTM Jun 2026$842.9M +13.2%+14.6%8.5%
REGNRegeneron Pharmaceuticals, Inc.LTM Jun 2026$528.6M +3.6%+16.8%3.4%
VRTXVertex Pharmaceuticals IncorporatedLTM Jun 2026$222.1M +11.2%+12.3%1.8%
UTHRUnited Therapeutics CorporationLTM Jun 2026$91.5M +14.8%+18.6%2.9%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$55.3M +97.1%-33.0%5.5%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$54.76M -3.1%+7.8%1.1%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$28.19M +36.7%+0.9%2.9%
Peer median (excluding BIIB) $375.35M+11.0%+9.3%3.2%

Competitors are the stored peer set for BIIB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income1.73B2.96B1.16B1.63B1.29B
Depreciation & Amortization487.7M518.4M494.8M673.2M779.9M
Deferred Income Tax(426.8M)(168.6M)(305.8M)(158.1M)361.6M
Stock-Based Compensation238.6M254.1M264.2M291.2M290.8M
Change in Working Capital(145.5M)(890.3M)(648.7M)(155.2M)(1.06B)
Accounts Receivables326M(222.4M)56.7M194.2M42.1M
Inventory(462.4M)(320.2M)(130.9M)(273.8M)(64.7M)
Accounts Payables00000
Other Working Capital(9.1M)(347.7M)(574.5M)(75.6M)(1.04B)
Other Non-Cash Items1.76B(1.29B)581.2M592.2M537M
Operating Cash Flow3.64B1.38B1.55B2.88B2.2B
Capital Expenditures(258.1M)(240.3M)(311.4M)(359.8M)(153.8M)
Acquisitions (Net)28.1M595M(6.91B)(1.07B)0
Purchases of Investments(3.81B)(3.45B)(5.14B)0(1.26B)
Sales of Investments3.5B4.66B8.29B551.5M79.7M
Other Investing Activities12.9M24.4M(11.3M)83.9M(38.7M)
Investing Cash Flow(563.7M)1.59B(4.09B)(799.2M)(1.37B)
Debt Repayment(170M)(1B)187.3M(650M)(16.9M)
Common Stock Issued(700K)(1.9M)(44.3M)(31.3M)(10M)
Common Stock Repurchased(1.8B)(750M)000
Dividends Paid00000
Other Financing Activities(115.5M)(5.6M)(6M)(2.2M)(275M)
Financing Cash Flow(2.09B)(1.76B)137M(683.5M)(301.9M)
Effect of Forex Changes(59.8M)(55.7M)35.1M(67.7M)101.9M
Net Change in Cash930.2M1.16B(2.37B)1.33B633.5M
Free Cash Flow3.38B1.14B1.24B2.52B2.05B

Biogen Inc.

NASDAQ:BIIB

Intrinsic Alpha fair value

Locked

Current Price

$251.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.